Governor Secures $4.1 Million Investment Into Levittown Pharma Firm Will Create 70 New Jobs
by Alex Lloyd Gross
Apozeal Pharmaceuticals Inc is going to expand their Levittown facility. According to Governor Shapiro’s office, Apozeal currently owns 11 FDA-approved Abbreviated New Drug Application (ANDA) products along with several over-the-counter (OTC) items for cough, cold, pain, and fever. At present, the company produces four of those products. Through this expansion, Apozeal will add new production lines at its 70,000-square-foot, FDA-registered facility in Levittown, enabling it to manufacture the remaining seven ANDA products and additional OTC products.
Apozeal Pharmaceuticals traces its roots back to Biopharm Inc., a contract drug manufacturer founded by pharmacists in 1992. In 2018, Biopharm’s assets were acquired by Torrent Pharmaceuticals Inc. In 2023, Apozeal acquired the Levittown facility with the goal of manufacturing its FDA-approved products domestically — aiming to produce 100% of its products in the United States.
This project was coordinated by Governor Shapiro’s BusinessPA team, an experienced group of economic development professionals dedicated to helping businesses succeed in Pennsylvania through tailored guidance, strategic partnerships, and financial resources.Whether based in the Commonwealth, another state, or across the globe, the team moves at the speed of business to set up companies for long-term growth and success here in Pennsylvania.
“We’d like to thank Governor Shapiro and his team for their support and investment of $1.1 million towards this expansion,” said Sadath Shareef, Chairman and CEO of Apozeal. “Their support was instrumental in helping bring this project to life. Through this expansion, we are bringing 70 new jobs to the region, and will have the opportunity to greatly expand our product line.”